Allen C Steere1, Gail McHugh, Nitin Damle, Vijay K Sikand. 1. Center for Immunology and Inflammatory Diseases, Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. asteere@partners.org
Abstract
BACKGROUND: Tests to determine serum antibody levels-the 2-tier sonicate immunoglobulin M (IgM) and immunoglobulin G (IgG) enzyme-linked immunosorbent assay (ELISA) and Western blot method or the IgG of the variable major protein-like sequence-expressed (VlsE) sixth invariant region (C6) peptide ELISA method-are the major tests available for support of the diagnosis of Lyme disease. However, these tests have not been assessed prospectively. METHODS: We used these tests prospectively to determine serologic responses in 134 patients with various manifestations of Lyme disease, 89 patients with other illnesses (with or without a history of Lyme disease), and 136 healthy subjects from areas of endemicity and areas in which the infection was not endemic. RESULTS: With 2-tier tests and the C6 peptide ELISA, only approximately one-third of 76 patients with erythema migrans had results that were positive for IgM or IgG seroreactivity with Borrelia burgdorferi in acute-phase samples. During convalescence, 3-4 weeks later, almost two-thirds of patients had seroreactivity with the spirochete B. burgdorferi. The frequencies of seroreactivity were significantly greater among patients with spirochetal dissemination than they were among those who lacked evidence of disseminated disease. Of the 44 patients with Lyme disease who had neurologic, heart, or joint involvement, all had positive C6 peptide ELISA results, 42 had IgG responses with 2-tier tests, and 2 patients with facial palsy had only IgM responses. However, among the control groups, the IgG Western blot was slightly more specific than the C6 peptide ELISA. The differences between the 2 test systems (2-tier testing and C6 peptide ELISA) with respect to sensitivity and specificity were not statistically significant. CONCLUSIONS: Except in patients with erythema migrans, both test systems were sensitive for support of the diagnosis of Lyme disease. However, with current methods, 2-tier testing was associated with slightly better specificity.
BACKGROUND: Tests to determine serum antibody levels-the 2-tier sonicate immunoglobulin M (IgM) and immunoglobulin G (IgG) enzyme-linked immunosorbent assay (ELISA) and Western blot method or the IgG of the variable major protein-like sequence-expressed (VlsE) sixth invariant region (C6) peptide ELISA method-are the major tests available for support of the diagnosis of Lyme disease. However, these tests have not been assessed prospectively. METHODS: We used these tests prospectively to determine serologic responses in 134 patients with various manifestations of Lyme disease, 89 patients with other illnesses (with or without a history of Lyme disease), and 136 healthy subjects from areas of endemicity and areas in which the infection was not endemic. RESULTS: With 2-tier tests and the C6 peptide ELISA, only approximately one-third of 76 patients with erythema migrans had results that were positive for IgM or IgG seroreactivity with Borrelia burgdorferi in acute-phase samples. During convalescence, 3-4 weeks later, almost two-thirds of patients had seroreactivity with the spirochete B. burgdorferi. The frequencies of seroreactivity were significantly greater among patients with spirochetal dissemination than they were among those who lacked evidence of disseminated disease. Of the 44 patients with Lyme disease who had neurologic, heart, or joint involvement, all had positive C6 peptide ELISA results, 42 had IgG responses with 2-tier tests, and 2 patients with facial palsy had only IgM responses. However, among the control groups, the IgG Western blot was slightly more specific than the C6 peptide ELISA. The differences between the 2 test systems (2-tier testing and C6 peptide ELISA) with respect to sensitivity and specificity were not statistically significant. CONCLUSIONS: Except in patients with erythema migrans, both test systems were sensitive for support of the diagnosis of Lyme disease. However, with current methods, 2-tier testing was associated with slightly better specificity.
Authors: Henry M Feder; Barbara J B Johnson; Susan O'Connell; Eugene D Shapiro; Allen C Steere; Gary P Wormser; W A Agger; H Artsob; P Auwaerter; J S Dumler; J S Bakken; L K Bockenstedt; J Green; R J Dattwyler; J Munoz; R B Nadelman; I Schwartz; T Draper; E McSweegan; J J Halperin; M S Klempner; P J Krause; P Mead; M Morshed; R Porwancher; J D Radolf; R P Smith; S Sood; A Weinstein; S J Wong; L Zemel Journal: N Engl J Med Date: 2007-10-04 Impact factor: 91.245
Authors: Gary P Wormser; Raymond J Dattwyler; Eugene D Shapiro; John J Halperin; Allen C Steere; Mark S Klempner; Peter J Krause; Johan S Bakken; Franc Strle; Gerold Stanek; Linda Bockenstedt; Durland Fish; J Stephen Dumler; Robert B Nadelman Journal: Clin Infect Dis Date: 2006-10-02 Impact factor: 9.079
Authors: J J Nocton; B J Bloom; B J Rutledge; D H Persing; E L Logigian; C H Schmid; A C Steere Journal: J Infect Dis Date: 1996-09 Impact factor: 5.226
Authors: Rendi Murphree Bacon; Brad J Biggerstaff; Martin E Schriefer; Robert D Gilmore; Mario T Philipp; Allen C Steere; Gary P Wormser; Adriana R Marques; Barbara J B Johnson Journal: J Infect Dis Date: 2003-04-02 Impact factor: 5.226
Authors: Naila Makhani; Shaun K Morris; Andrea V Page; Jason Brophy; L Robbin Lindsay; Brenda L Banwell; Susan E Richardson Journal: J Clin Microbiol Date: 2010-11-10 Impact factor: 5.948
Authors: Gary P Wormser; Aimee T Tang; Natasha R Schimmoeller; Susan Bittker; Denise Cooper; Paul Visintainer; Maria E Aguero-Rosenfeld; Katarina Ogrinc; Franc Strle; Gerold Stanek Journal: Med Microbiol Immunol Date: 2013-11-12 Impact factor: 3.402
Authors: Susan C Lipsett; John A Branda; Alexander J McAdam; Louis Vernacchio; Caroline D Gordon; Catherine R Gordon; Lise E Nigrovic Journal: Clin Infect Dis Date: 2016-06-28 Impact factor: 9.079
Authors: Katherine B Sulka; Klemen Strle; Jameson T Crowley; Robert B Lochhead; Robert Anthony; Allen C Steere Journal: Arthritis Rheumatol Date: 2018-09-24 Impact factor: 10.995
Authors: Richard B Porwancher; C Greg Hagerty; Jianqing Fan; Lisa Landsberg; Barbara J B Johnson; Mark Kopnitsky; Allen C Steere; Karen Kulas; Susan J Wong Journal: Clin Vaccine Immunol Date: 2011-03-02
Authors: Gary P Wormser; Martin Schriefer; Maria E Aguero-Rosenfeld; Andrew Levin; Allen C Steere; Robert B Nadelman; John Nowakowski; Adriana Marques; Barbara J B Johnson; J Stephen Dumler Journal: Diagn Microbiol Infect Dis Date: 2012-10-11 Impact factor: 2.803